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Background: Fusion genes are chimeric results originated from previous separate genes with aberrant functions.
The resulting protein products may lead to abnormal status of expression levels, functions and action sites, which in
return may cause the abnormal proliferation of cells and cancer development.
Results: With the emergence of next-generation sequencing technology, RNA-seq has spurred gene fusion discovery
in various cancer types. In this work, we compiled 591 recently published RNA-seq datasets in 15 kinds of
human cancer, and the gene fusion events were comprehensively identified. Based on the results, a database
was developed for gene fusion in cancers (FusionCancer), with the attempt to provide a user-friendly utility for the
cancer research community. A flexible query engine has been developed for the acquisition of annotated information
of cancer fusion genes, which would help users to determine the chimera events leading to functional
changes. FusionCancer can be accessible at the following hyperlink website: http://donglab.ecnu.edu.cn/
databases/FusionCancer/
Conclusion: To the best of our knowledge, FusionCancer is the first comprehensive fusion gene database
derived only from cancer RNA-seq data.Introduction
Fusion gene is a chimera product due to the consolida-
tion of two separate genes, which can occur as a conse-
quence of chromosomal structural changes, such as
inversion, deletion, amplification or inter-chromosomal/
intra-chromosomal translocation [1]. Gene fusion can
bring dramatic expression changes compared to previous
separate genes because of the regulatory domain dis-
placement, and the resulting chimeric protein-coding
transcript will either lose its original function or work
into a scabbed protein with functions descended from
both its ancestors [2]. As a consequence of accumulation
of hereditary variations, cancer can also be the result of
gene fusion, especially the fusions related to kinases or
transcription controllers [3]. Considering their preva-
lence and common characteristics across diverse human
cancer types, gene fusions are always regarded as a* Correspondence: wuzh3000@126.com; ddong.ecnu@gmail.com
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EML4-ALK fusion event in lung cancer have been iden-
tified [4], and play important role in tumor metastasis.
Previously, the fusion events were detected mainly based
on RT-PCR, which is not suitable for massively identify
fusion genes in cancers.
Although the occurrence of gene fusion events in solid
tumor has long been noted, the importance has been
realized due to the emergence of next-generation se-
quencing technology, such as transcriptome sequencing
(RNA-seq) [3]. RNA-seq permits genome-wide novel
transcript analysis, and spurred gene fusion discovery
from diverse human cancers, including prostate, breast,
lung and bladder carcinoma [4–7], etc. Up to date, huge
amount of cancer RNA-seq data have been available,
which provided us an opportunity to comprehensively
identify the fusion genes. Meanwhile, algorithms and
pipelines provided great convenience for the gene fusion
detection [8–11], and many software have been developed
with high sensitivity and specificity [12–15]. One obvious
benefit of gene fusion discovery based on RNA-seq data is
the potential to detect novel gene fusion events.icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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issued, such as chimerDB [16] and HYBRIDdb [17].
They are either manually curated database of published
literatures or by mapping EST sequences to the human
genome to find cancer-related fusion genes in human,
which lead to a lower coverage of gene fusions. In this
work, we retrieved recently published RNA-seq data in
15 kinds of human cancer, and comprehensively detected
the gene fusion events using four gene fusion detection
methods. A user-friendly database, FusionCancer, was
developed with the attempt to facilitate the cancer gene
fusion researches. FusionCancer is provided with an
integrated web-based utility, which made our predicted
gene fusion events easily accessible to cancer research
community.
Data Content
RNA-seq method can allow identification of gene fu-
sions in individual cancer samples and facilitate compre-
hensive characterization of cellular transcriptome. A
huge amount of RNA-seq based cancer transcriptome
data are available, which provided valuable resources forFig. 1 The data acquisition and database construction pipelineus to comprehensively identify gene fusion events in
cancers. As shown in Fig. 1, we searched NCBI
Sequence Read Archive (SRA, http://www.ncbi.nlm.nih.
gov/sra) database [18] for single-end (SE) and pair-end
(PE) RNA-seq data in diverse cancer types with the
following search terms: ‘cancer’ , ‘carcinoma’ and ‘RNA-
seq’. The data included in this work have to meet the
following criteria: 1) the length of sequencing reads is
larger than 36 bp; 2) the data is cancer-related. Finally, a
total of 591 cancer samples, published between 2008
and 2014, were selected for further processing (Table 1).
The samples included in our database focused on 15
types of cancers. All sequencing raw data were down-
loaded, and a software named fastq-dump in the SRA
Toolkit version 2.3.2 Linux package [19] was obtained
from SRA Software page to convert sra format to fastq
format with default parameters. We removed the low
quality sequencing reads prior to analyzing these data.
Two criteria were used in this step: 1) removing reads
with adaptors; 2) removing reads with unknown ‘N’
bases. All subsequent analyses to detect fusion genes
were based on these filtered sequencing reads.
Table 1 List of cancer types and number of RNA-seq dataset
included in our work
Cancer types Number of datasets
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rapid development due to the emergence of next-
generation sequencing technology. In this work, four
popular fusion gene detection software (Tophat2 [14],
FusionMap [12], SOAPfuse [15], and chimerascan [13]
were employed in our pipeline. The former two soft-
ware can process both single-end and paired-end
datasets, while the latter two can only deal with
single-end data. We aligned all short reads to the hu-
man genome (UCSC hg19), and identified a prelimin-
ary set of fusion genes by selecting all the gene-gene
pairs. Next, in-build filtering steps were performed,
and fusion events were retained if they meet at least
one of the following criteria: 1) fusion event formed
by two distant genes (with a distance larger than
100000); 2) with a recurrence rate () larger than 0.2;
3) identified by at least two software; 4) containing at
least 10 supporting reads. At last, a total of 11,839
gene fusion events were identified based on at least
one software, and only 137 fusion genes were identi-
fied by all four software. The exon-level expressions
of fusion genes and wild-type parts of the fusion
genes were calculated by Reads Per Kilobase of tran-
script per Million mapped reads (RPKM). In addition,
COSMIC [20] and chimerDB [16] databases have
stored some previously documented known fusion
genes in different cancer types. We downloaded 288
fusion genes from COSMIC and chimerDB databases,
among which 209 fusion events can be found in our
FusionCancer database. So, we implemented these in-
formation into FusionCancer.Database implementation
The FusionCancer database is implemented with PHP,
MySQL on a Red Hat Linux system, and provides several
common gateway interface scripts to process user’s input
to search the database. A schematic diagram FusionCan-
cer organization is shown in Fig. 1, and FusionCancer can
be accessible at the following hyperlink website: http://
donglab.ecnu.edu.cn/databases/FusionCancer/
Retrieve data
FusionCancer provides two ways to query the database:
one is to search fusion genes of interests by keyword,
the other is to browse database by cancer types or chro-
mosomes. FusionCancer can be accessed with gene
symbols, and return a list of fusion genes, coupled with
biological implications, chromosome information and
nucleotide sequences. Three kinds of keywords (Gene
symbol, Database ID and Gene pairs) can be selected to
search fusion gene results. Moreover, users can select
fusion genes identified by a specific software. One the
other hand, all fusion genes can be viewed through the
Browse DB section by choosing a specific cancer type or
chromosome.
BLAST
To help users perform sequence similarity analysis,
BALST was provided in the database. A maximum size
of 50 k sequence file with fasta format is required. All
fusion sequences at transcription level discovered by
four software were used as BLAST database. And users
can perform sequence alignment using BLASTn search-
ing form and appropriate parameters listed in the
BLAST page.
Download
All datasets are available in this section. These data-
sets contain all predicted fusion genes by four soft-
ware, accompanied with the annotated information
and chimeric transcript sequences.
Conclusion
RNA-seq is a recently developed way to the transcriptome
profiling that uses massively parallel RNA-sequencing
technology [21]. The ability of RNA-seq to analyze the
whole transcriptome in an unbiased fashion makes it an
attractive technology to measure the dysregulation in can-
cers. Furthermore, it also allows identification of gene
fusion in individual cancer samples. With the attempt
to provide a more comprehensive cancer fusion gene
resource, we compiled recently published cancer RNA-
seq data and identified all possible gene fusion events
using four popular software. We presented an easily
accessible database, offering access to those identified
fusion genes. The integration of cancer fusion genes
Wang et al. Diagnostic Pathology  (2015) 10:131 Page 4 of 4can enhance the role of FusionCancer as an essential
resource for cancer fusion gene analysis. To the best of
our knowledge, FusionCancer is the first repository
centralizing cancer fusion genes identified from RNA-
seq datasets. The database not only provides a large
resource for cancer researches, but also supplies a plat-
form for tumor specific individual biomarker analysis.
Future direction
With the development of next-generation sequencing,
sequencing costs will drop substantially. More and more
cancer sequencing data would be available in the near
future, and these data can provide us valuable resource.
Moreover, it will be facilitated by the development of
improved bioinformatics procedures for the detection of
fusion genes from RNA-seq data. Future directions
include an incorporation of more cancer fusion genes
with higher accuracy.
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